Arena Pharmaceuticals, Inc.

Other

Ryan M Hart

Marlon Carlos

Graeme Semple

Lee Alani Selvey

Zezhi Jesse Shao

William Lucas Betts, Iii

Yun Shan

Paul Maffuid

Deam Windate Given, Iii

Tawfik Gharbaoui

Ashwin M Krishnan

Dipanjan Sengupta

Albert S Ren

Mark Macias

Jason B Ibarra

Edward A Lally

Nainesh Shah

Jonathan James Duffield

Vincent J Santora

Douglas M Park

Jeffrey Smith

Brian Smith

Marlon V Carlos

Deam Windate Iii Given

William L Iii Betts

Jeffrey A Schultz

The present invention relates to certain compositions of a 5-HTserotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.

Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto

The present invention relates to certain compositions of a 5-HTserotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.

[object Object]

The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HTserotonin receptor activity.  The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-HTserotonin receptor modulators, compositions thereof and methods of using the same.

The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HTserotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-HTserotonin receptor modulators, compositions thereof and methods of using the same.

Growing community of inventors

San Francisco, CA, United States of America

Ryan M Hart